Profile

Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat solid tumors by pioneering a differentiated approach to TIL (tumor-infiltrating lymphocytes) therapy. Building on the clinical validation in the field, Turnstone’s innovative TIL therapy is based on the identification, selection, and expansion of the most potent tumor-reactive T cells (Selected TILs), which have the potential to extend the therapeutic benefit to a broader set of solid tumor indications, beyond where current first-generation TILs have proven effective.

Turnstone Biologics  logo

Website

turnstonebio.com

Contact


Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences

Participants

33 in total